12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ciclesonide HFA: Phase III data

A double-blind, U.S. Phase III trial in 1,111 patients aged 12 and older showed that once-daily 74 and 148 µg ciclesonide HFA for 6 months each met the primary endpoint of significantly improving reflective TNSS from baseline to week 6 vs. placebo (p<0.001 for both). On secondary endpoints, low- and high-dose ciclesonide HFA significantly improved instantaneous TNSS from baseline to week 6 vs. placebo (p<0.01 for both). Both doses of ciclesonide HFA also significantly improved overall RQLQ scores from baseline to week 6 in...

Read the full 398 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >